Published in J Invest Dermatol on February 01, 1993
Membrane-type 1 matrix metalloproteinase cleaves CD44 and promotes cell migration. J Cell Biol (2001) 3.32
Interaction between CD44 and hyaluronate is directly implicated in the regulation of tumor development. J Exp Med (1994) 2.37
CD44 directs membrane-type 1 matrix metalloproteinase to lamellipodia by associating with its hemopexin-like domain. EMBO J (2002) 2.05
AP-1-mediated invasion requires increased expression of the hyaluronan receptor CD44. Mol Cell Biol (1997) 1.46
An essential role for CD44 variant isoforms in epidermal Langerhans cell and blood dendritic cell function. J Cell Biol (1997) 1.46
Hyaluronan-CD44 interaction hampers migration of osteoclast-like cells by down-regulating MMP-9. J Cell Biol (2002) 1.08
CD44/chondroitin sulfate proteoglycan and alpha 2 beta 1 integrin mediate human melanoma cell migration on type IV collagen and invasion of basement membranes. Mol Biol Cell (1996) 1.07
Reduced level of CD44 and hyaluronan associated with unfavorable prognosis in clinical stage I cutaneous melanoma. Am J Pathol (2000) 0.98
Targeted drug delivery utilizing protein-like molecular architecture. J Am Chem Soc (2007) 0.96
Expression of CD44 in effusions of patients diagnosed with serous ovarian carcinoma--diagnostic and prognostic implications. Clin Exp Metastasis (2000) 0.86
Effects of hyaluronan on the invasive properties of human breast cancer cells in vitro. Int J Exp Pathol (2001) 0.85
Application of Collagen-Model Triple-Helical Peptide-Amphiphiles for CD44-Targeted Drug Delivery Systems. J Drug Deliv (2012) 0.82
Focal loss of CD44 variant protein expression is related to recurrence in superficial bladder carcinoma. Am J Pathol (1999) 0.81
Isolation of All CD44 Transcripts in Human Epidermis and Regulation of Their Expression by Various Agents. PLoS One (2016) 0.75
The histogenesis and biologic behavior of primary human malignant melanomas of the skin. Cancer Res (1969) 13.27
CD44 is the principal cell surface receptor for hyaluronate. Cell (1990) 11.01
Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-beta and promotes tumor invasion and angiogenesis. Genes Dev (2000) 8.24
A 39-kDa protein on activated helper T cells binds CD40 and transduces the signal for cognate activation of B cells. Proc Natl Acad Sci U S A (1992) 4.77
Actin-binding protein requirement for cortical stability and efficient locomotion. Science (1992) 4.66
High glucose level and free fatty acid stimulate reactive oxygen species production through protein kinase C--dependent activation of NAD(P)H oxidase in cultured vascular cells. Diabetes (2000) 4.55
Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer (1996) 4.46
Long-term results of a multi-institutional randomized trial comparing prognostic factors and surgical results for intermediate thickness melanomas (1.0 to 4.0 mm). Intergroup Melanoma Surgical Trial. Ann Surg Oncol (2000) 3.42
Localization of matrix metalloproteinase 9 to the cell surface provides a mechanism for CD44-mediated tumor invasion. Genes Dev (1999) 3.32
A matrix metalloproteinase induction/activation system exists in the human left ventricular myocardium and is upregulated in heart failure. Circulation (2000) 2.94
Oncogenic H-ras stimulates tumor angiogenesis by two distinct pathways. Proc Natl Acad Sci U S A (1997) 2.88
GLUT1: a newly discovered immunohistochemical marker for juvenile hemangiomas. Hum Pathol (2000) 2.86
Clotrimazole inhibits cell proliferation in vitro and in vivo. Nat Med (1995) 2.76
Role of the clotting system in cell-mediated hypersensitivity. I. Fibrin deposition in delayed skin reactions in man. J Exp Med (1973) 2.75
Exogenous mesenchymal stem cells localize to the kidney by means of CD44 following acute tubular injury. Kidney Int (2007) 2.75
Efficacy of an elective regional lymph node dissection of 1 to 4 mm thick melanomas for patients 60 years of age and younger. Ann Surg (1996) 2.68
The classification of malignant melanoma and its histologic reporting. Cancer (1973) 2.67
Nonfamilial cutaneous melanoma incidence in women associated with sun exposure before 20 years of age. Pediatrics (1989) 2.61
Atypical Spitz nevi/tumors: lack of consensus for diagnosis, discrimination from melanoma, and prediction of outcome. Hum Pathol (1999) 2.50
CD44 isoforms containing exon V3 are responsible for the presentation of heparin-binding growth factor. J Cell Biol (1995) 2.38
Interaction between CD44 and hyaluronate is directly implicated in the regulation of tumor development. J Exp Med (1994) 2.37
Common and uncommon melanocytic nevi and borderline melanomas. Semin Oncol (1975) 2.36
Melanoma in children. N Engl J Med (1995) 2.35
Distinct cellular functions mediated by different VLA integrin alpha subunit cytoplasmic domains. Cell (1992) 2.33
High actin concentrations in brain dendritic spines and postsynaptic densities. Proc Natl Acad Sci U S A (1982) 2.31
Benign cutaneous adnexal tumors with combined folliculosebaceous, apocrine, and eccrine differentiation. Clinicopathologic and immunohistochemical study of eight cases. Am J Dermatopathol (1996) 2.30
CD44H regulates tumor cell migration on hyaluronate-coated substrate. J Cell Biol (1992) 2.28
Early recognition of potentially fatal necrotizing fasciitis. The use of frozen-section biopsy. N Engl J Med (1984) 2.24
Distinct effects of two CD44 isoforms on tumor growth in vivo. J Exp Med (1991) 2.23
Defective expression of the CD40 ligand in X chromosome-linked immunoglobulin deficiency with normal or elevated IgM. Proc Natl Acad Sci U S A (1993) 2.17
Matrix metalloproteinase-7-mediated cleavage of Fas ligand protects tumor cells from chemotherapeutic drug cytotoxicity. Cancer Res (2001) 2.12
Leu-8/TQ1 is the human equivalent of the Mel-14 lymph node homing receptor. Nature (1989) 2.12
Induction of apoptosis of metastatic mammary carcinoma cells in vivo by disruption of tumor cell surface CD44 function. J Exp Med (1997) 2.11
Efficacy of 2-cm surgical margins for intermediate-thickness melanomas (1 to 4 mm). Results of a multi-institutional randomized surgical trial. Ann Surg (1993) 2.08
Long-term results of a prospective surgical trial comparing 2 cm vs. 4 cm excision margins for 740 patients with 1-4 mm melanomas. Ann Surg Oncol (2001) 2.06
Sarcomas: genetics, signalling, and cellular origins. Part 1: The fellowship of TET. J Pathol (2007) 2.03
The primary structure of the human leukocyte antigen CD37, a species homologue of the rat MRC OX-44 antigen. J Exp Med (1989) 1.99
Kimura's disease and angiolymphoid hyperplasia with eosinophilia: two distinct histopathological entities. J Cutan Pathol (1987) 1.92
Automatic differentiation of melanoma from melanocytic nevi with multispectral digital dermoscopy: a feasibility study. J Am Acad Dermatol (2001) 1.91
Nonepidermal origin of malignant melanoma associated with a giant congenital nevocellular nevus. Plast Reconstr Surg (1981) 1.86
Organization and function of stress fibers in cells in vitro and in situ. A review. Cell Muscle Motil (1984) 1.85
Dermal dendritic melanocytic proliferations: an update. Histopathology (2004) 1.84
Narrower margins for clinical stage I malignant melanoma. N Engl J Med (1982) 1.82
Primary melanoma of the skin: recognition and management. J Am Acad Dermatol (1980) 1.82
Curcumin is an in vivo inhibitor of angiogenesis. Mol Med (1998) 1.81
A new immunologic marker for human Langerhans cells. N Engl J Med (1981) 1.79
Identification of hyaluronic acid binding sites in the extracellular domain of CD44. J Cell Biol (1993) 1.77
A unique microvascular phenotype shared by juvenile hemangiomas and human placenta. Arch Dermatol (2001) 1.77
Melasma: a clinical, light microscopic, ultrastructural, and immunofluorescence study. J Am Acad Dermatol (1981) 1.76
Basophilic leukocytes in allergic contact dermatitis. J Exp Med (1972) 1.75
Rejection of first-set skin allografts in man. the microvasculature is the critical target of the immune response. J Exp Med (1979) 1.74
Long-term quality of life after laparoscopy-assisted distal gastrectomy for gastric cancer. Surg Endosc (2007) 1.73
Characterization of Langerhans cells by the use of monoclonal antibodies. Lab Invest (1981) 1.73
Organ distribution in rats of two members of the low-density lipoprotein receptor gene family, gp330 and LRP/alpha 2MR, and the receptor-associated protein (RAP). J Histochem Cytochem (1994) 1.72
Prognostic factors for melanoma patients with lesions 0.76 - 1.69 mm in thickness. An appraisal of "thin" level IV lesions. Ann Surg (1982) 1.72
Dysplastic melanocytic nevi: a reproducible histologic definition emphasizing cellular morphology. Mod Pathol (1989) 1.71
Pilomatrix carcinoma or calcifying epitheliocarcinoma of Malherbe: a case report and review of literature. Cancer (1980) 1.70
Transformations in the structure of the cytoplasmic ground substance in erythrophores during pigment aggregation and dispersion. I. A study using whole-cell preparations in stereo high voltage electron microscopy. J Cell Biol (1977) 1.70
Morphology of delayed-type hypersensitivity reactions in man. II. Ultrastructural alterations affecting the microvasculature and the tissue mast cells. Lab Invest (1976) 1.70
Morphology of delayed type hypersensitivity reactions in man. I. Quantitative description of the inflammatory response. Lab Invest (1974) 1.68
Lentigo maligna and lentigo-maligna melanoma. Am J Pathol (1969) 1.68
Squamoid eccrine ductal carcinoma. Histopathology (1997) 1.67
The clinical diagnosis, classification and histogenetic concepts of the early stages of cutaneous malignant melanomas. N Engl J Med (1971) 1.65
Isolation of cDNAs for two distinct human Fc receptors by ligand affinity cloning. EMBO J (1988) 1.60
Matrix metalloproteinase inhibition attenuates left ventricular remodeling and dysfunction in a rat model of progressive heart failure. Circulation (2001) 1.59
Studies on the cellular origin of neurothekeoma: clinical, light microscopic, immunohistochemical, and ultrastructural observations. J Am Acad Dermatol (1991) 1.59
Histopathologic diagnosis of dysplastic nevi: concordance among pathologists convened by the World Health Organization Melanoma Programme. Hum Pathol (1991) 1.54
Natural ligands of the B cell adhesion molecule CD22 beta carry N-linked oligosaccharides with alpha-2,6-linked sialic acids that are required for recognition. J Biol Chem (1993) 1.49
Clinical findings, cutaneous pathology, and response to therapy in 21 patients with keratosis pilaris atrophicans. Arch Dermatol (1994) 1.49
Bullous dermatosis of hemodialysis. Ann Intern Med (1975) 1.47
CD22, a B cell-specific immunoglobulin superfamily member, is a sialic acid-binding lectin. J Biol Chem (1993) 1.46
Marginal zone lymphoma (low-grade B-cell lymphoma of mucosa-associated lymphoid tissue type) of skin and subcutaneous tissue: a study of 15 patients. Am J Surg Pathol (1996) 1.45
The natural break points for primary-tumor thickness in clinical Stage I melanoma. N Engl J Med (1981) 1.45
Actin-binding protein expression in benign and malignant melanocytic proliferations. Hum Pathol (1994) 1.44
Origin of cutaneous melanoma in a congenital dysplastic nevus spilus. Arch Dermatol (1990) 1.43
Glycosylation provides both stimulatory and inhibitory effects on cell surface and soluble CD44 binding to hyaluronan. J Cell Biol (1998) 1.43
Early melanoma. Histologic terms. Am J Dermatopathol (1991) 1.43
Regulation of CD44 binding to hyaluronan by glycosylation of variably spliced exons. J Cell Biol (1995) 1.43
Late administration of monoclonal antibody to leukocyte function-antigen 1 abrogates incipient murine cerebral malaria. Eur J Immunol (1991) 1.42
Acral lentiginous melanoma (including in situ melanoma) arising in association with naevocellular naevi. Melanoma Res (1996) 1.42
Adjuvant high-dose interferon alfa-2b in patients with high-risk melanoma. Cancer J (2000) 1.41
Topical axitinib suppresses angiogenesis pathways induced by pulsed dye laser. Br J Dermatol (2014) 1.40
A prognostic model for clinical stage I melanoma of the upper extremity. The importance of anatomic subsites in predicting recurrent disease. Ann Surg (1981) 1.38
Prognostic factors for patients with clinical stage I melanoma of intermediate thickness (1.51 - 3.39 mm). A conceptual model for tumor growth and metastasis. Ann Surg (1982) 1.38
Growth inhibition of murine melanoma and human colon carcinoma by recombinant human platelet factor 4. J Natl Cancer Inst (1990) 1.37
Congenital melanocytic nevi of the small and garment type. Clinical, histologic, and ultrastructural studies. Hum Pathol (1973) 1.36
Inhibition of tumor growth in vivo with a soluble CD44-immunoglobulin fusion protein. J Exp Med (1992) 1.36
Inhibition of tumor growth in vivo by hyaluronan oligomers. Int J Cancer (1998) 1.35
Bullous pemphigoid, an ultrastructural study of the inflammatory response: eosinophil, basophil and mast cell granule changes in multiple biopsies from one patient. J Invest Dermatol (1982) 1.35
Stress fibers in cells in situ: immunofluorescence visualization with antiactin, antimyosin, and anti-alpha-actinin. J Cell Biol (1982) 1.35
Angiogenesis and tumor progression of melanoma. Quantification of vascularity in melanocytic nevi and cutaneous malignant melanoma. Lab Invest (1992) 1.34
Malignant melanoma. Prognostic significance of "microscopic satellites" in the reticular dermis and subcutaneous fat. Ann Surg (1981) 1.34
A prognostic model for clinical stage I melanoma of the lower extremity. Location on foot as independent risk factor for recurrent disease. Surgery (1981) 1.33
Glycosylation of CD44 is implicated in CD44-mediated cell adhesion to hyaluronan. J Cell Biol (1996) 1.31
Risk factors for cutaneous melanoma. A practical method of recognizing predisposed individuals. JAMA (1987) 1.30